Institute of Pathology, Charité University Medicine Berlin
Berlin, 10117, Germany
Completed
NCT Number: NCT01215474
Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC
While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).
Completed
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- NSCLC Stadium III-IV
Exclusion criteria
- no NSCLC or different stadium
Sponsors and collaborators
Lead sponsor
Provitro GmbH
Industry
Collaborators
- AstraZeneca
- Charite University, Berlin, Germany
Registry information
Important dates
- First posted
- Oct 6, 2010
- Registry last updated
- Jun 16, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.